Research and development of next generation of antibody-based therapeutics
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Research and development of next generation of antibody-based therapeutics
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume 31, Issue 9, Pages 1198-1207
Publisher
Springer Nature
Online
2010-08-09
DOI
10.1038/aps.2010.120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Development of a Fully Human Anti-PDGFRβ Antibody That Suppresses Growth of Human Tumor Xenografts and Enhances Antitumor Activity of an Anti-VEGFR2 Antibody
- (2015) Juqun Shen et al. NEOPLASIA
- A Therapeutic Anti-VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
- (2010) Y. A. Yeung et al. CANCER RESEARCH
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- Antibody-Drug Conjugate Targets
- (2009) B. Teicher CURRENT CANCER DRUG TARGETS
- Developing intrabodies for the therapeutic suppression of neurodegenerative pathology
- (2009) Anne Messer et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Structural characterization of a human Fc fragment engineered for extended serum half-life
- (2009) Vaheh Oganesyan et al. MOLECULAR IMMUNOLOGY
- Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
- (2008) M K Robinson et al. BRITISH JOURNAL OF CANCER
- Durable complete responses from therapy with combined epratuzumab and rituximab
- (2008) John P. Leonard et al. CANCER
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
- (2008) Roberto Stasi et al. CANCER TREATMENT REVIEWS
- Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold
- (2008) Per-Åke Nygren FEBS Journal
- Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies
- (2008) Julien Lejeune et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
- (2008) L. J. Holt et al. PROTEIN ENGINEERING DESIGN & SELECTION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started